Vimarsana
Biggest News Aggregation in the World

Ted Yednock News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ted Yednock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ted Yednock Today - Breaking & Trending Today

Silverarc Capital Management LLC Increases Stake in Annexon, Inc. (NASDAQ:ANNX) - Vimarsana News

Silverarc Capital Management LLC Increases Stake in Annexon, Inc. (NASDAQ:ANNX)

Silverarc Capital Management LLC increased its position in shares of Annexon, Inc. (NASDAQ:ANNX – Free Report) by 2.5% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 399,716 shares of the company’s stock after purchasing an additional 9,805 shares during the period. Silverarc Capital Management LLC’s holdings in Annexon were worth $943,000 as of […]

Source: wkrb13.com
Silverarc Capital Management LLC Acquires 9,805 Shares of Annexon, Inc. (NASDAQ:ANNX) - Vimarsana News

Silverarc Capital Management LLC Acquires 9,805 Shares of Annexon, Inc. (NASDAQ:ANNX)

Silverarc Capital Management LLC boosted its holdings in Annexon, Inc. (NASDAQ:ANNX – Free Report) by 2.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 399,716 shares of the company’s stock after purchasing an additional 9,805 shares during the quarter. Silverarc Capital Management LLC […]

Annexon, Inc. (NASDAQ:ANNX) Sees Large Increase in Short Interest - Vimarsana News

Annexon, Inc. (NASDAQ:ANNX) Sees Large Increase in Short Interest

Annexon, Inc. (NASDAQ:ANNX – Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,280,000 shares, a growth of 16.9% from the December 15th total of 1,950,000 shares. Based on an average daily volume of 712,800 shares, the […]

Source: wkrb13.com
Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway - Vimarsana News

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated...